Lorem ipsum dolor sit amet
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit
15K articles and news from our archive.
Working in the chemical industry has always been challenging. Boring times hardly ever happened, due to the overall cyclicity of the business and constantly changing market conditions with the associated imperative to…
In 2025, Indena significantly upgraded its facilities, marking a substantial advancement in the quality, versatility, and reliability of its CDMO services for partners. These strategic improvements primarily focus on the GMP…
In 2024, CDMO and pharma companies delivered a mixed performance. Many met or even surpassed their growth targets, but performance varied significantly across modalities, segments, and geographies. North American CDMOs outperformed their…
Generic pharmaceuticals have revolutionized the healthcare industry since they entered the market over five decades ago. They have expanded patient access to medications by providing more affordable alternatives to costly brand-name…
Antibody-drug conjugate (ADCs) combine cytotoxic agents with specific antibodies through chemical linkers, with the goal of delivering drugs directly to a target within a patient’s body, and offer the potential of selective…
Olon has a long-standing reputation in API manufacturing, but what drives the company beyond simply producing APIs? At Olon, our mission goes far beyond manufacturing APIs. We are driven by the belief…
Synopsis Chemspec Europe 2025 began with a dramatic twist—the evacuation of thousands of CHEMSPEC visitors staying in hotels close to Koeln Messe due to the discovery of unexploded World War II bombs…
Looking Ahead: Growth, Innovation, and Continuity 2025 marks PROCOS’ 80th anniversary. How did you celebrate this important milestone? 2025 has been a truly special year for PROCOS. We began by…
Introduction In 2004, the U.S. Food and Drug Administration (FDA) introduced a visionary framework for pharmaceutical manufacturing modernization based on two foundational pillars: Quality by Design (QbD) and Process Analytical Technology (PAT)…
Introduction A startup company is defined as a new venture created to bring new products or services to the market in conditions of great uncertainty. The objective of a startup is to…
For major pharma brands, for which pharmacovigilance (PV) has up to now primarily involved monitoring long-established drugs for potential side effects over time, adverse event (AE) case management has been seen first…
Introduction Spray freeze drying forms a frozen pellet from liquid under cryogenic conditions as droplets are formed and pass through a tower. Subsequently, the frozen pellets as a bulk bed of particles…
Since their initial publication in 2001, proteolysis-targeting chimeras (PROTACs) have rapidly progressed from an academic concept to a promising new therapeutic modality (1). Over the past two decades, they’ve captured the imagination…
Introduction Modern R&D organizations, from global pharmaceutical giants to specialized biotech and CDMOs, invest vast time, talent, and capital in developing breakthrough drugs, cell and gene therapies, vaccines, and new ingredients. But…
COMMENTARY ARTICLE Beyond partnerships: redefining cdmo-biotech collaboration in the age of complexity Operational Chemistry: Making Biotech–CDMO Teams Actually Work Introduction As the landscape of therapeutic development rapidly evolves, so do the…
